Boichut, Morgane ; Université de Liège - ULiège > Département des maladies infectieuses et parasitaires (DMI) ; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France
Poussard, Margaux ; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France ; Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg
Roussel, Xavier ; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France ; Service d'hématologie clinique, CHU Besançon, Besançon, France
Belakri, Imane; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France
Biichlé, Sabeha ; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France
Fredon, Maxime ; CARLA Biotherapeutics, Besançon, France
Renosi, Florian; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France ; Laboratoire d'onco-hématologie moléculaire, CHU Besançon, Besançon, France
Boidot, Romain ; Unit of Molecular Biology, Department of Biology and Pathology of Tumors, Georges-François Leclerc Anticancer Center, UNICANCER, Dijon, France
Adotevi, Olivier ; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France ; Service d'oncologie médicale, CHU Besançon, Besançon, France
Brooks, Christopher; Menarini Group, New York, NY
Garnache-Ottou, Francine; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France ; Laboratoire d'immunologie cellulaire et hématologie, CHU Besançon, Besançon, France
Angelot Delettre, Fanny; Université Marie et Louis Pasteur, EFS, INSERM, UMR Right, Besançon, France
Language :
English
Title :
New leads to enhance tagraxofusp efficacy in pDC-AML.
Xiao, W, Chan, A, Waarts, MR, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood 137:10 (2021), 1377–1391.
Zalmaï, L, Viailly, PJ, Biichle, S, et al. Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape. Haematologica 106:12 (2021), 3056–3066.
Facchetti, F, Cigognetti, M, Fisogni, S, Rossi, G, Lonardi, S, Vermi, W, Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol 29:2 (2016), 98–111.
Pemmaraju, N, Konopleva, M, Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 4:16 (2020), 4020–4027.
Lucas, N, Duchmann, M, Rameau, P, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 33:10 (2019), 2466–2480.
Zhu, L, Wang, P, Zhang, W, et al. Plasmacytoid dendritic cell infiltration in acute myeloid leukemia. Cancer Manag Res 12 (2020), 11411–11419.
Hercus, TR, Dhagat, U, Kan, WLT, et al. Signalling by the βc family of cytokines. Cytokine Growth Factor Rev 24:3 (2013), 189–201.
Philippe, L, Ceroi, A, Bôle-Richard, E, et al. Bortezomib as a new therapeutic approach for blastic plasmacytoid dendritic cell neoplasm. Haematologica 102:11 (2017), 1861–1868.
Sapienza, MR, Fuligni, F, Agostinelli, C, et al. Molecular profiling of blastic plasmacytoid dendritic cell neoplasm reveals a unique pattern and suggests selective sensitivity to NF-kB pathway inhibition. Leukemia 28:8 (2014), 1606–1616.
Wingelhofer, B, Neubauer, HA, Valent, P, et al. Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. Leukemia 32:8 (2018), 1713–1726.
Sepúlveda, P, Encabo, A, Carbonell-Uberos, F, Miñana, MD, BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Differ 14:2 (2007), 378–380.
Zudaire, E, Cuesta, N, Murty, V, et al. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest 118:2 (2008), 640–650.
Jackson, JT, Mulazzani, E, Nutt, SL, Masters, SL, The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration. J Biol Chem, 297(2), 2021, 100905.
Wang, B, Reville, PK, Yassouf, MY, et al. Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies. Nat Commun, 15(1), 2024, 1821.
Krishnan, A, Pagane, M, Roshal, M, et al. Evaluation of tagraxofusp (SL-401) alone and in combination with ruxolitinib for the treatment of myeloproliferative neoplasms. Blood, 134(suppl 1), 2019, 2967.
LoRusso, PM, Adjei, AA, Varterasian, M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:23 (2005), 5281–5293.
